PGP and Alzheimer disease: Globally, the current knowledge supports the idea that P-gp is downregulated at BBB of AD and PD patients and that restoration of P-gp expression levels and/or the increase in P-gp activity by inducers and activators, respectively, could meet a potential application in the therapy of these neurological disorders.